Safety considerations for statins

Chiara Bolego, Roberta Baetta, Stefano Bellosta, Alberto Corsini, Rodolfo Paoletti

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Purpose of review: The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins. Recent findings: The withdrawal of cerivastatin from the global market in 2001, because of severe cases of rhabdomyolysis, highlighted concerns regarding the safety of the entire class. Afterwards, the role of statins and their interactions with other drugs in precipitating this condition have been carefully reviewed. In approximately 60% of the total number of cases, statin-related rhabdomyolysis was found to be related to drug/drug interactions. Recently, all cases of fatal rhabdomyolysis associated with statin use have been reported to the US Food and Drug Administration. This has shown that fatal rhabdomyolysis among statin users is a rare event, the reporting rates being much less than one death per million prescriptions in the case of all statins except cerivastatin. Summary: The safety and tolerability of the available statins support their use as the first-line treatment of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh the small risk of myopathy. Nevertheless, clinicians should be aware of the adverse effects possibly related to statin therapy, particularly in patients at high risk for coronary heart disease and requiring long-term multiple-drug therapies.

Original languageEnglish
Pages (from-to)637-644
Number of pages8
JournalCurrent Opinion in Lipidology
Volume13
Issue number6
DOIs
Publication statusPublished - Dec 2002

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Safety
Rhabdomyolysis
Drug interactions
Coronary Disease
Pharmaceutical Preparations
Muscular Diseases
Drug Interactions
Drug therapy
Pharmacokinetics
United States Food and Drug Administration
Prescriptions
Oxidoreductases
Therapeutics

Keywords

  • Drug interactions
  • Myopathy
  • Pharmacokinetics
  • Rhabdomyolysis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Safety considerations for statins. / Bolego, Chiara; Baetta, Roberta; Bellosta, Stefano; Corsini, Alberto; Paoletti, Rodolfo.

In: Current Opinion in Lipidology, Vol. 13, No. 6, 12.2002, p. 637-644.

Research output: Contribution to journalArticle

Bolego, Chiara ; Baetta, Roberta ; Bellosta, Stefano ; Corsini, Alberto ; Paoletti, Rodolfo. / Safety considerations for statins. In: Current Opinion in Lipidology. 2002 ; Vol. 13, No. 6. pp. 637-644.
@article{fcdb219550894de199bc7ed1504fa9a3,
title = "Safety considerations for statins",
abstract = "Purpose of review: The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins. Recent findings: The withdrawal of cerivastatin from the global market in 2001, because of severe cases of rhabdomyolysis, highlighted concerns regarding the safety of the entire class. Afterwards, the role of statins and their interactions with other drugs in precipitating this condition have been carefully reviewed. In approximately 60{\%} of the total number of cases, statin-related rhabdomyolysis was found to be related to drug/drug interactions. Recently, all cases of fatal rhabdomyolysis associated with statin use have been reported to the US Food and Drug Administration. This has shown that fatal rhabdomyolysis among statin users is a rare event, the reporting rates being much less than one death per million prescriptions in the case of all statins except cerivastatin. Summary: The safety and tolerability of the available statins support their use as the first-line treatment of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh the small risk of myopathy. Nevertheless, clinicians should be aware of the adverse effects possibly related to statin therapy, particularly in patients at high risk for coronary heart disease and requiring long-term multiple-drug therapies.",
keywords = "Drug interactions, Myopathy, Pharmacokinetics, Rhabdomyolysis",
author = "Chiara Bolego and Roberta Baetta and Stefano Bellosta and Alberto Corsini and Rodolfo Paoletti",
year = "2002",
month = "12",
doi = "10.1097/00041433-200212000-00007",
language = "English",
volume = "13",
pages = "637--644",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Safety considerations for statins

AU - Bolego, Chiara

AU - Baetta, Roberta

AU - Bellosta, Stefano

AU - Corsini, Alberto

AU - Paoletti, Rodolfo

PY - 2002/12

Y1 - 2002/12

N2 - Purpose of review: The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins. Recent findings: The withdrawal of cerivastatin from the global market in 2001, because of severe cases of rhabdomyolysis, highlighted concerns regarding the safety of the entire class. Afterwards, the role of statins and their interactions with other drugs in precipitating this condition have been carefully reviewed. In approximately 60% of the total number of cases, statin-related rhabdomyolysis was found to be related to drug/drug interactions. Recently, all cases of fatal rhabdomyolysis associated with statin use have been reported to the US Food and Drug Administration. This has shown that fatal rhabdomyolysis among statin users is a rare event, the reporting rates being much less than one death per million prescriptions in the case of all statins except cerivastatin. Summary: The safety and tolerability of the available statins support their use as the first-line treatment of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh the small risk of myopathy. Nevertheless, clinicians should be aware of the adverse effects possibly related to statin therapy, particularly in patients at high risk for coronary heart disease and requiring long-term multiple-drug therapies.

AB - Purpose of review: The hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins. Recent findings: The withdrawal of cerivastatin from the global market in 2001, because of severe cases of rhabdomyolysis, highlighted concerns regarding the safety of the entire class. Afterwards, the role of statins and their interactions with other drugs in precipitating this condition have been carefully reviewed. In approximately 60% of the total number of cases, statin-related rhabdomyolysis was found to be related to drug/drug interactions. Recently, all cases of fatal rhabdomyolysis associated with statin use have been reported to the US Food and Drug Administration. This has shown that fatal rhabdomyolysis among statin users is a rare event, the reporting rates being much less than one death per million prescriptions in the case of all statins except cerivastatin. Summary: The safety and tolerability of the available statins support their use as the first-line treatment of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh the small risk of myopathy. Nevertheless, clinicians should be aware of the adverse effects possibly related to statin therapy, particularly in patients at high risk for coronary heart disease and requiring long-term multiple-drug therapies.

KW - Drug interactions

KW - Myopathy

KW - Pharmacokinetics

KW - Rhabdomyolysis

UR - http://www.scopus.com/inward/record.url?scp=0036909541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036909541&partnerID=8YFLogxK

U2 - 10.1097/00041433-200212000-00007

DO - 10.1097/00041433-200212000-00007

M3 - Article

C2 - 12441888

AN - SCOPUS:0036909541

VL - 13

SP - 637

EP - 644

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 6

ER -